Thursday, October 26, 2017 10:55:18 PM
Is PKTX The Next ORMP?
Oct. 23, 2017 5:24 PM
ProtoKinetix, Incorporated, PKTX is a small molecular biotechnology company based in West Virginia that has been announcing major progress recently, and has some investors thinking that its’ starting to look like an early-stage version of another biopharma platform technology company that is making major waves in treating diabetes, Oramed Pharmaceuticals Inc., ORMP.
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) is a clinical-stage pharmaceutical company based in Israel that has developed a unique proprietary platform technology that allows for the oral delivery of drugs presently administered only via injection. The Company has a $143M market cap as of October 21st, 2017, and its stock is up 76% since this February.
Most of the attributed reason for the stock surge stems from the successful conclusion of their Phase IIb trial of its oral insulin capsule ORMD-0801 in the treatment of type 2 diabetes, and the anticipation of the beginning of its Phase III trials.
In September 2017, ORMD announced that it successfully concluded its meeting with the U.S. Food and Drug Administration (FDA), getting clear guidance that the regulatory pathway for submission of ORMD-0801 would be a Biologics License Application (BLA).
ProtoKinetix, Incorporated (OTC:OTCQB:PKTX) is a much smaller company with a $16M market cap, but like ORMD, it too is a platform technology company with many potential applications. The company is actively developing their patented family of hyper stable, potent glycopeptides (AAGP™) that enhance the engraftment and protection of transplanted cells used in regenerative medicine.
Amongst the various indications PKTX is researching are Kidney Ischemia, Normothermic Liver Perfusion, Retinal Cell Replacement, and Monoclonal Antibody Production. However, like ORMD, they are further along in clinical trials investigating its ability to help treat Type 1 Diabetes. The Company is currently in Phase II of a first-in-human clinical trial being conducted by a well-respected team at the University of Alberta that started in March 2017. Much of what will drive the PKTX story going forward is the success of this trial.
Besides the strong science behind the PKTX story, it is heartening to see that the company has done an excellent job of balance sheet management. There is no debt on the books, and for a biotech company, it has a remarkably small burn of only $1M in SG&A on a yearly basis.
At some point, soon I see PKTX as a prime takeover candidate. Likely won’t happen until trial results begin to come out, which I would expect to see sometime in early in 2018. Novo Nordisk, (NYSE:NVO) and Eli Lilly, (NYSE:LLY) are both active in the Type 1 diabetes space and would be on the list of companies interested in acquiring them.
It should also be noted that the CEO has funded a significant amount of the development himself, and owns 24% of the Company, and is only paying himself a salary of $1. That is unheard of among small-cap biotechs. Most of often a management team owns very little stock and pays themselves exorbitant salaries. It’s nice to see a management team be “all-in” like the folks at PKTX. With no debt and an extremely small burn, there is very little downside to the stock at this point. At these levels, it is a great place to accumulate and hold until we begin to see the data from the trials.
Disclosure: I am/we are long ORMP, PKTX.
Recent ORMP News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/23/2024 12:06:24 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 09/16/2024 08:42:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 08:05:24 PM
- Oramed Letter to Shareholders • PR Newswire (US) • 06/26/2024 01:05:00 PM
- Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock • PR Newswire (US) • 06/26/2024 01:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 06/20/2024 11:32:05 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/20/2024 11:30:08 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 09:28:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 09:15:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 09:00:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 01:00:27 PM
- Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation • GlobeNewswire Inc. • 03/19/2024 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 10:00:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 01:42:26 PM
- Oramed Letter to Shareholders • PR Newswire (US) • 02/20/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 10:30:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 09:45:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:45:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:43:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:41:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:40:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:39:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:37:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:36:18 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM